EC approves Takeda’s Fruzaqla for metastatic colorectal cancer
Drug ApprovalPhase 3License out/in
Preview
Source: Pharmaceutical Technology
Takeda holds the licence for developing, marketing and manufacturing fruquintinib outside of mainland China, Hong Kong and Macau. Credit: Tada Images / Shutterstock.
The European Commission (EC) has approved Takeda’s Fruzaqla (fruquintinib) as a monotherapy for adults with metastatic colorectal cancer who have exhausted currently available standard therapies.
This approval is for patients who have advanced on or are not tolerant to treatments including trifluridine-tipiracil and regorafenib.
In April 2024, the treatment received a positive opinion from the Committee for Medicinal Products for Human Use.
The latest development comes after the US Food and Drug Administration (FDA) granted approval for the same indication in November 2023.
The approval is based on data from the Phase III multi-regional FRESCO-2 trial assessing Fruzaqla along with best supportive care (BSC) versus placebo plus BSC.
See Also:Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease
Preview
Source: Pharmaceutical Technology
AstraZeneca’s Truqap and Faslodex combo receives approval in EU
Preview
Source: Pharmaceutical Technology
The trial met all primary and key secondary efficacy endpoints with the treatment demonstrating benefit regardless of patients’ previous therapy types.
The oral inhibitor had a manageable safety profile with adverse reactions that led to discontinuation of treatment.
Takeda holds the sole global licence for developing, marketing and manufacturing fruquintinib outside mainland China, Hong Kong and Macau.
A submission for Fruzaqla was made to the Japan Pharmaceuticals and Medical Devices Agency in September 2023.
Fruquintinib is developed and marketed by Hutchmed in China.
It was first approved by the China National Medical Products Administration in September 2018 and commercially launched in China in November of the same year under the brand name ELUNATE.
Takeda Global oncology business unit president Teresa Bitetti stated: “The approval marks an important moment for the colorectal cancer community in the EU. For the first time in over a decade, patients with previously treated metastatic colorectal cancer have a new targeted treatment option that can be used irrespective of whether their tumours harbour actionable mutations.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.